- Home
- VRAX
as 07-26-2024 4:00pm EST
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
| Founded: | 2013 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.9M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 116.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.60 - $4.30 | Next Earning Date: | 08-06-2024 |
| Revenue: | $79,301 | Revenue Growth: | -27.79% |
| Revenue Growth (this year): | 16580.29% | Revenue Growth (next year): | 477.17% |
Latest Virax Biolabs Group Limited News
VRAX Breaking Stock News: Dive into VRAX Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
Top Premarket Gainers
Benzinga
3 months ago
EXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral Syndromes
PR Newswire
3 months ago
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
PR Newswire
3 months ago
Virax Biolabs to Participate at ESCMID Global 2024
PR Newswire
4 months ago
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
GlobeNewswire
6 months ago
Cemtrex Receives $0.8 Million Additional Vicon Industries Order from School District Customer
GlobeNewswire
6 months ago
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
GlobeNewswire
6 months ago
Digital Ally Announces University Security Order
Compare VRAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRAX Virax Biolabs Group Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.